1. Home
  2. CRTO vs WVE Comparison

CRTO vs WVE Comparison

Compare CRTO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$20.40

Market Cap

1.1B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$18.54

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
WVE
Founded
2005
2012
Country
France
Singapore
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
CRTO
WVE
Price
$20.40
$18.54
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$38.67
$19.08
AVG Volume (30 Days)
471.4K
9.2M
Earning Date
10-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
83.79
N/A
EPS
3.00
N/A
Revenue
$1,956,800,000.00
$109,230,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.42
$31.09
P/E Ratio
$7.01
N/A
Revenue Growth
0.53
103.75
52 Week Low
$19.00
$5.28
52 Week High
$47.27
$19.60

Technical Indicators

Market Signals
Indicator
CRTO
WVE
Relative Strength Index (RSI) 49.13 88.69
Support Level $19.00 $6.93
Resistance Level $21.48 $7.78
Average True Range (ATR) 0.78 0.86
MACD 0.08 0.75
Stochastic Oscillator 56.45 91.86

Price Performance

Historical Comparison
CRTO
WVE

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: